Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Artemisinin-transferrin conjugate retards growth of breast tumors in the rat.

Lai H, Nakase I, Lacoste E, Singh NP, Sasaki T.

Anticancer Res. 2009 Oct;29(10):3807-10.

2.

Effects of artemisinin-tagged holotransferrin on cancer cells.

Lai H, Sasaki T, Singh NP, Messay A.

Life Sci. 2005 Jan 28;76(11):1267-79. Epub 2004 Nov 23.

PMID:
15642597
3.

Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds.

Lai H, Sasaki T, Singh NP.

Expert Opin Ther Targets. 2005 Oct;9(5):995-1007. Review.

PMID:
16185154
5.

Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.

Jiang XP, Wang F, Yang DC, Elliott RL, Head JF.

Anticancer Res. 2002 Sep-Oct;22(5):2685-92.

PMID:
12529982
6.

Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation.

Nakase I, Lai H, Singh NP, Sasaki T.

Int J Pharm. 2008 Apr 16;354(1-2):28-33. Epub 2007 Sep 6. Review.

PMID:
17942255
7.

Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide.

Oh S, Kim BJ, Singh NP, Lai H, Sasaki T.

Cancer Lett. 2009 Feb 8;274(1):33-9. doi: 10.1016/j.canlet.2008.08.031. Epub 2008 Oct 5.

PMID:
18838215
8.

Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis.

Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, Goodlett DR, Tanaka S, Futaki S, Lai H, Sasaki T.

Cancer Lett. 2009 Feb 18;274(2):290-8. doi: 10.1016/j.canlet.2008.09.023. Epub 2008 Nov 8.

PMID:
19006645
9.

Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo.

Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, Wang S, Sasaki T.

Anticancer Res. 2011 Dec;31(12):4111-4.

PMID:
22199268
10.

Artemisinin induces apoptosis in human cancer cells.

Singh NP, Lai HC.

Anticancer Res. 2004 Jul-Aug;24(4):2277-80.

11.
12.

Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study.

Elliott RL, Elliott MC, Wang F, Head JF.

Ann N Y Acad Sci. 1993 Nov 30;698:159-66. Review.

PMID:
8279755
13.

Development of a dihydroartemisinin-resistant Molt-4 leukemia cell line.

Park J, Lai HC, Singh M, Sasaki T, Singh NP.

Anticancer Res. 2014 Jun;34(6):2807-10.

PMID:
24922643
14.

Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells.

Singh NP, Lai HC.

Anticancer Res. 2005 Nov-Dec;25(6B):4325-31.

15.

Anticancer activities of artemisinin and its bioactive derivatives.

Firestone GL, Sundar SN.

Expert Rev Mol Med. 2009 Oct 30;11:e32. doi: 10.1017/S1462399409001239. Review.

PMID:
19883518
16.

Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer.

Elliott RL, Stjernholm R, Elliott MC.

Cancer Detect Prev. 1988;12(1-6):469-80.

PMID:
3180141
17.

Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.

Gong Y, Gallis BM, Goodlett DR, Yang Y, Lu H, Lacoste E, Lai H, Sasaki T.

Anticancer Res. 2013 Jan;33(1):123-32.

PMID:
23267137
18.

Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat.

Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK.

Cancer Lett. 1995 Nov 27;98(1):83-7.

PMID:
8529210
19.

Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin.

Gharib A, Faezizadeh Z, Mesbah-Namin SA, Saravani R.

Daru. 2014 May 28;22:44. doi: 10.1186/2008-2231-22-44.

20.

Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma.

Wang F, Elliott RL, Head JF.

Anticancer Res. 1999 Jan-Feb;19(1A):445-50.

PMID:
10226580
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk